Evaluation of the Role of Brain Natriuretic Peptide in Acute Coronary Syndrome .

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The measurements of the natriuretic peptide are useful and beneficial for risk stratification irrespective of the cause during admission time or during hospital stay course. the aim of the study is to Assessment of the role of Brain natriuretic peptide in diagnosis of acute coronary syndrome . Evaluation of the relation of Brain natriuretic peptide to the severity and occurrence of complications in acute coronary syndrome .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ischemic heart disease (IHD) is regarded as one of the important leading causes of disability and death across the globe.

Acute coronary syndrome (ACS) applies to a variety of events reporting ischemia, ranging from stable angina without myocardial necrosis to ST -segment elevation myocardial infarction (STEMI). The need for prevention and detection of coronary vascular disease as early as possible by using newer and more cost effective tools is suggested . For risk stratification in patients with ACS, serial ECG monitoring and cardiac biomarkers measurement are needed as part of the diagnostic workup. B-type natriuretic peptide is synthesized as a high molecular weight precursor pro-brain natriuretic peptide (BNP) which is cleaved to release BNP and the amino-terminal fragment, N-terminal pro (NT-pro) BNP. Both peptides are released from the cardiac ventricles in response to the increased wall stress and hence its levels may indicate ventricular strain BNP is believed to have its role as natriuretic hormone and vasodilation. Among other effects are inhibition of the Renin Angiotensin-Aldosterone system(RAAS), and sympathetic nervous system. After an ischemic occurrence, BNP levels peak in 14 to 40 hours .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndromes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Brain natriuretic peptide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1

patients with Acute Coronary Syndrome , this group will be sub classified into: Non-ST-elevation myocardial infarction (NSTEMI) ST-elevation myocardial infarction (STEMI) Unstable angina

No interventions assigned to this group

group 2

apparently healthy patients will be included in this study as a control group for comparison

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with acute coronary syndrome.

Exclusion Criteria

* Patients with previous MI
* Eection fraction (EF) less than 30%
* Patients having cardiomyopathy
* Patients having renal, liver, malignant, infectious, or inflammatory diseases .

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mennat-Allah Gamal kamel Mohamed

resident doctor at Assiut University hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mennat-Allah Gamal kamel Mohamed, resident doctor

Role: CONTACT

Phone: +201098695613

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Volterrani M, Iellamo F, Senni M, Piepoli MF. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. Int J Cardiol. 2017 Jan 1;226:132-135. doi: 10.1016/j.ijcard.2016.04.180. Epub 2016 May 7.

Reference Type BACKGROUND

PMID: 27184730 (View on PubMed)

Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991 Apr;87(4):1402-12. doi: 10.1172/JCI115146.